Legacy

In 1983 the proposition that a globally significant pharmaceutical manufacturer could be founded in India, without a foreign parent, a proprietary technology or a state licence, was untested. India had a large and capable generics industry, but it supplied a domestic market and exported principally to countries with limited regulatory infrastructure. The idea that an Indian company could sell at scale into the United States, on the FDA’s terms, was aspiration rather than record.

Sun Pharma is one of the clearest demonstrations that it could be done. The company entered the United States in 1997 by buying a small, troubled Detroit manufacturer, and by the 2026 financial year held 552 approved abbreviated new drug applications and 57 approved new drug applications there, with an innovative-medicines business past one billion dollars. The demonstration matters independently of the company’s future: it changed what a founder in Ahmedabad or Hyderabad could plausibly aim at.

India supplies roughly a fifth of the world’s generic medicines by volume and hosts the largest number of US FDA-approved manufacturing plants outside the United States. That capability is the mechanism by which medicines discovered and priced for wealthy health systems become affordable elsewhere after patent expiry.

Sun Pharma’s share of that contribution is concentrated in chronic therapies — psychiatry, cardiology, diabetology, dermatology, ophthalmology — and in complex dosage forms that are technically hard to replicate and therefore slow to fall in price without a capable manufacturer. It is a specific rather than a general contribution, and it is better measured in the availability of particular products in particular markets than in a single headline figure.

Many large companies founded by a single individual do not survive that individual’s authority intact. The test is structural: does operating power transfer, and to whom?

Sun Pharma’s answer has been deliberate and gradual. Long-horizon research was separated into a distinct listed company, SPARC, in 2007. Operating authority passed to Kirti Ganorkar, a twenty-nine-year company executive, on 1 September 2025, with Shanghvi becoming Executive Chairman. Family members hold executive directorships rather than the chief operating role. The board carries a lead independent director and independent members drawn from industry, medicine, finance and market research.

None of this guarantees continuity. It does mean that the company has been designed as something capable of outlasting its founder, rather than assumed to be so.

The most transferable part of the record is not the scale but the sequence. Enter where competition is weakest rather than where the market is largest. Integrate backwards so that cost and quality are owned rather than rented. Buy capability — plants, approvals, molecules, prescriber access — instead of buying turnover. Keep leverage low so that a difficult acquisition costs profit rather than solvency. Change the product when the market changes rather than defending a position that has stopped working.

Each of these is visible in the public record at a specific date, and none of them requires exceptional capital or exceptional science to begin. That is what makes the example useful rather than merely impressive.

Shanghvi’s institutional roles — the central board of the Reserve Bank of India from 2018, the chairmanship of the IIT Bombay Board of Governors from 2016, trusteeship of the Rhodes Trust from 2017 — place him in a small group of Indian business figures whose judgement is sought on questions well outside their own industry.

His philanthropy runs through the Shantilal Shanghvi Foundation, named for his father, supporting eye care, cancer care and school education. The Cornea Institute at the L. V. Prasad Eye Institute in Hyderabad carries the foundation’s name. His 2015 investment of ₹1,800 crore for a 23 per cent stake in Suzlon Energy, then a distressed wind-turbine manufacturer, was an unusual step for a pharmaceutical entrepreneur and remains his most significant commitment outside medicine.